Pablo Tebas
Pablo Tebas
Potvrđena adresa e-pošte na
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
P Tebas, D Stein, WW Tang, I Frank, SQ Wang, G Lee, SK Spratt, ...
New England Journal of Medicine 370 (10), 901-910, 2014
Maraviroc for previously treated patients with R5 HIV-1 infection
RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ...
New England Journal of Medicine 359 (14), 1429-1441, 2008
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
P Tebas, WG Powderly, S Claxton, D Marin, W Tantisiriwat, SL Teitelbaum, ...
AIDS (London, England) 14 (4), F63, 2000
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz …
GA McComsey, D Kitch, ES Daar, C Tierney, NC Jahed, P Tebas, L Myers, ...
Journal of Infectious Diseases 203 (12), 1791-1801, 2011
Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1
S Naggie, C Cooper, M Saag, K Workowski, P Ruane, WJ Towner, ...
New England Journal of Medicine 373 (8), 705-713, 2015
Prevalence and predictive value of intermittent viremia with combination HIV therapy
DV Havlir, R Bassett, D Levitan, P Gilbert, P Tebas, AC Collier, MS Hirsch, ...
Jama 286 (2), 171-179, 2001
Bone disease in HIV infection: a practical review and recommendations for HIV care providers
GA McComsey, P Tebas, E Shane, MT Yin, ET Overton, JS Huang, ...
Clinical infectious diseases 51 (8), 937-946, 2010
Effect of HIV antibody VRC01 on viral rebound after treatment interruption
KJ Bar, MC Sneller, LJ Harrison, JS Justement, ET Overton, ME Petrone, ...
New England Journal of Medicine 375 (21), 2037-2050, 2016
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
G Fätkenheuer, M Nelson, A Lazzarin, I Konourina, AIM Hoepelman, ...
New England Journal of Medicine 359 (14), 1442-1455, 2008
Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ...
The Journal of infectious diseases 210 (3), 354-362, 2014
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
R Bedimo, NM Maalouf, S Zhang, H Drechsler, P Tebas
Aids 26 (7), 825-831, 2012
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus—infected individuals
K Mondy, K Yarasheski, WG Powderly, M Whyte, S Claxton, D DeMarco, ...
Clinical Infectious Diseases 36 (4), 482-490, 2003
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
DV Havlir, IC Marschner, MS Hirsch, AC Collier, P Tebas, RL Bassett, ...
New England Journal of Medicine 339 (18), 1261-1268, 1998
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
DV Havlir, NS Hellmann, CJ Petropoulos, JM Whitcomb, AC Collier, ...
Jama 283 (2), 229-234, 2000
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind …
J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, ...
The Lancet 390 (10107), 2063-2072, 2017
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations
C Hoffmann, N Minkah, J Leipzig, G Wang, MQ Arens, P Tebas, ...
Nucleic acids research 35 (13), e91, 2007
Safety and immunogenicity of an anti–Zika virus DNA vaccine
P Tebas, CC Roberts, K Muthumani, EL Reuschel, SB Kudchodkar, ...
New England Journal of Medicine 385 (12), e35, 2021
HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D
M Cozzolino, M Vidal, MV Arcidiacono, P Tebas, KE Yarasheski, ...
Aids 17 (4), 513-520, 2003
A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia
V Amorosa, M Synnestvedt, R Gross, H Friedman, RR MacGregor, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 39 (5), 557-561, 2005
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
MP Dube, RA Parker, P Tebas, SK Grinspoon, RA Zackin, GK Robbins, ...
Aids 19 (16), 1807-1818, 2005
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20